#67 Notable Clinical Interest
Emerging findings or policy developments worth monitoring closely.
Clinicians should be cautious about recommending topical CBD products for pain or soreness until robust clinical evidence supports efficacy, as this recent study suggests the benefits may be overstated. Patients currently using topical CBD should be counseled that limited scientific evidence supports its use for musculoskeletal complaints, and clinicians should discuss evidence-based alternatives such as topical NSAIDs or physical therapy. This finding is particularly relevant for primary care providers who face increasing patient demand for CBD products driven by marketing claims rather than clinical data.
A recent study examining topical cannabidiol (CBD) for musculoskeletal soreness found insufficient evidence to support claims of analgesic or anti-inflammatory benefit, challenging widespread consumer beliefs about this product category. While CBD has demonstrated promise in preclinical models and some clinical contexts for conditions like anxiety and sleep disturbance, the evidence base for topical CBD specifically addressing localized pain and inflammation remains limited and inconsistent. This finding is clinically significant given the proliferation of over-the-counter CBD topical products marketed directly to patients for muscle and joint soreness without robust efficacy data. Clinicians should be cautious about endorsing topical CBD for pain management until higher-quality randomized controlled trials establish clear therapeutic benefit and optimal dosing strategies. When counseling patients interested in topical CBD products, practitioners should clarify the distinction between emerging laboratory evidence and proven clinical effectiveness, while considering evidence-based alternatives with established efficacy for musculoskeletal complaints. Patients seeking topical CBD for soreness should be informed that current evidence does not strongly support its use, and they should discuss proven pain management options with their healthcare provider.
“The evidence for topical CBD in managing localized soreness remains preliminary at best, and I tell my patients honestly that we simply don’t have the rigorous clinical trials yet to support it as a first-line treatment, even though the mechanistic rationale is sound. What we do know is that topical cannabinoids won’t produce systemic effects, so the risk profile is favorable, but that’s not the same as proven efficacy, and I won’t pretend it is just because patients want it to work.”
💊 While topical cannabidiol products have gained considerable consumer popularity for musculoskeletal complaints, the emerging clinical evidence remains preliminary and heterogeneous in quality. The pharmacokinetic barriers to transdermal penetration of CBD, combined with limited high-quality randomized controlled trials specifically examining topical formulations, mean that current endorsements often outpace robust scientific support. Important confounders include variable product quality and CBD concentration across the largely unregulated market, placebo effects in pain perception, and the difficulty of isolating CBD’s contribution from other ingredients in commercial preparations. Clinicians should counsel patients that while topical CBD is generally well-tolerated and may be considered a low-risk adjunct, evidence supporting its efficacy for localized soreness remains inconclusive, and patients should not delay or replace established treatments such as physical therapy or topical NSAIDs without additional clinical evidence. Until larger, well-designed trials are
This topic comes up in consultations often.
Dr. Caplan offers clinical context on evolving cannabis policy and its real-world implications for patients.
Book a consultation →💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
